Diagnosis and classification of Crohn's disease

Molodecky, 2012, Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review, Gastroenterology, 142, 46, 10.1053/j.gastro.2011.10.001 Baumgart, 2012, Crohn's disease, Lancet, 380, 1590, 10.1016/S0140-6736(12)60026-9 Khor, 2011, Genetics and pathogenesis of inflammatory bowel disease, Nature, 474, 307, 10.1038/nature10209 Baumgart, 2005, Patients with active inflammatory bowel disease lack immature peripheral blood plasmacytoid and myeloid dendritic cells, Gut, 54, 228, 10.1136/gut.2004.040360 Franke, 2010, Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci, Nat Genet, 42, 1118, 10.1038/ng.717 Jostins, 2012, Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease, Nature, 491, 119, 10.1038/nature11582 Clevers, 2009, Inflammatory bowel disease, stress, and the endoplasmic reticulum, N Engl J Med, 360, 726, 10.1056/NEJMcibr0809591 Glocker, 2009, Inflammatory bowel disease and mutations affecting the interleukin-10 receptor, N Engl J Med, 361, 2033, 10.1056/NEJMoa0907206 Jung, 2012, Genotype/phenotype analyses for 53 Crohn's disease associated genetic polymorphisms, PLoS One, 7, e52223, 10.1371/journal.pone.0052223 Cleynen, 2012, Genetic factors conferring an increased susceptibility to develop Crohn's disease also influence disease phenotype: results from the IBDchip European Project, Gut Logan, 2010, The geoepidemiology of autoimmune intestinal disease, Autoimmun Rev, 9, A372, 10.1016/j.autrev.2009.11.008 Walker, 1978, Possible diagnostic test for Crohn's disease by use of buccal mucosa, Lancet, 2, 759, 10.1016/S0140-6736(78)92648-X Stöcker, 1984, Autoantikörper gegen exokrines Pankreas und gegen intestinale Becherzellen in der Diagnostik des Morbus Crohn und der Colitis ulcerosa, Dt med Wschr, 109, 1963, 10.1055/s-2008-1069485 Roggenbuck, 2009, Identification of GP2, the major zymogen granule membrane glycoprotein, as the autoantigen of pancreatic antibodies in Crohn's disease, Gut, 58, 1620, 10.1136/gut.2008.162495 Hase, 2009, Uptake through glycoprotein 2 of FimH+bacteria by M cells initiates mucosal immune response, Nature, 462, 226, 10.1038/nature08529 Werner, 2012, Identification of pancreatic glycoprotein 2 as an endogenous immunomodulator of innate and adaptive immune responses, J Immunol, 189, 2774, 10.4049/jimmunol.1103190 Van Assche, 2010, European Crohn's and Colitis Organisation (ECCO). The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis, J Crohns Colitis, 4, 7, 10.1016/j.crohns.2009.12.003 Schirbel, 2010, Impact of pain on health-related quality of life in patients with inflammatory bowel disease, World J Gastroenterol, 16, 3168, 10.3748/wjg.v16.i25.3168 Vavricka, 2011, Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort, Am J Gastroenterol, 106, 110, 10.1038/ajg.2010.343 Lennard-Jones, 1989, Classification of inflammatory bowel disease, Scand J Gastroenterol Suppl, 170, 2, 10.3109/00365528909091339 Tolan, 2010, MR enterographic manifestations of small bowel Crohn disease, Radiographics, 30, 367, 10.1148/rg.302095028 Pearce, 2012, Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours: a retrospective cohort study, Lancet, 380, 499, 10.1016/S0140-6736(12)60815-0 Peyrin-Biroulet, 2010, The natural history of adult Crohn's disease in population-based cohorts, Am J Gastroenterol, 105, 289, 10.1038/ajg.2009.579 Thia, 2010, Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort, Gastroenterology, 139, 1147, 10.1053/j.gastro.2010.06.070 Van Limbergen, 2008, Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease, Gastroenterology, 135, 1114, 10.1053/j.gastro.2008.06.081 Conrad, 2002, Serological differentiation of inflammatory bowel diseases, Eur J Gastroenterol Hepatol, 14, 1, 10.1097/00042737-200202000-00006 Bossuyt, 2006, Serologic markers in inflammatory bowel disease, Clin Chem, 52, 171, 10.1373/clinchem.2005.058560 Komorowski, 2013, Autoantibodies against exocrine pancreas in Crohn's disease are directed against two antigens: the glycoproteins CUZD1 and GP2, J Crohns Colitis, 7, 780, 10.1016/j.crohns.2012.10.011 Bogdanos, 2011, Diagnostic value, clinical utility and pathogenic significance of reactivity to the molecular targets of Crohn's disease specific-pancreatic autoantibodies, Autoimmun Rev, 11, 143, 10.1016/j.autrev.2011.09.004 Li, 2008, New serological biomarkers of inflammatory bowel disease, World J Gastroenterol, 14, 5115, 10.3748/wjg.14.5115 Silverberg, 2005, Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology, Can J Gastroenterol, 19, 5, 10.1155/2005/269076 Levine, 2011, Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification, Inflamm Bowel Dis, 17, 1314, 10.1002/ibd.21493 Best, 1976, Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study, Gastroenterology, 70, 439, 10.1016/S0016-5085(76)80163-1 Harvey, 1980, A simple index of Crohn's-disease activity, Lancet, 1, 514, 10.1016/S0140-6736(80)92767-1 Turner, 2010, Appraisal of the pediatric Crohn's disease activity index on four prospectively collected datasets: recommended cutoff values and clinimetric properties, Am J Gastroenterol, 105, 2085, 10.1038/ajg.2010.143 Magro, 2013, European consensus on the histopathology of inflammatory bowel disease, J Crohns Colitis, 7, 827, 10.1016/j.crohns.2013.06.001